Clinical trial
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
NCT00062491 · BioNumerik Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00062491 |
|---|---|
| Title | Study of Karenitecin (BNP1350) to Treat Malignant Melanoma |
| Official title | Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma |
| Lead sponsor | BioNumerik Pharmaceuticals, Inc., Industry |
| Collaborators | Crown Bioscience Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Neoplasm |
| Intervention type | Drug |
| Interventions | Karenitecin (BNP1350) |
| Enrollment | 46 |
| Start date | May 1, 2002 |
| Primary completion | Jun 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | Jun 12, 2003 |
| Last update posted | Mar 12, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: